Integrating menin inhibitors into the treatment landscape of AML: Future directions
AML Hub3 Sep 2025

Integrating menin inhibitors into the treatment landscape of AML: Future directions

The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for his thoughts on the topic “Integrating menin inhibitors into the treatment landscape of AML: Future directions”. Zeidner provides an overview of the latest clinical trial data on menin inhibitors in the treatment of NPM1-mutated or KMT2A-rearranged AML presented at the European Hematology Association 2025 Congress.


This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Episoder(33)

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation fro...

19 Jan 20min

Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance

Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance

The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the prese...

14 Jan 16min

ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety

ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New Yo...

13 Jan 8min

ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML

ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital...

18 Des 20257min

Clinical research round-up: Current and emerging treatments for IDH1-mutated AML

Clinical research round-up: Current and emerging treatments for IDH1-mutated AML

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myelo...

6 Nov 20254min

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial da...

24 Okt 20257min

Addressing uncertainty in patient selection for transplant in AML

Addressing uncertainty in patient selection for transplant in AML

During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussio...

22 Sep 202523min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
treningspodden
foreldreradet
merry-quizmas
dopet
jakt-og-fiskepodden
rss-sunn-okonomi
podme-bio-3
rss-strid-de-norske-borgerkrigene
hverdagspsyken
sovnlos
rss-kull
sinnsyn
gravid-uke-for-uke
tomprat-med-gunnar-tjomlid
rss-var-forste-kaffe
dypdykk
rss-kunsten-a-leve